Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Nano ; 2(3): 449-56, 2008 Mar.
Article in English | MEDLINE | ID: mdl-19206569

ABSTRACT

In this paper we report the synthesis and characterization of organically modified silica (ORMOSIL) nanoparticles, covalently incorporating the fluorophore rhodamine-B, and surface-functionalized with a variety of active groups. The synthesized nanoparticles are of ultralow size (diameter approximately 20 nm), highly monodispersed, stable in aqueous suspension, and retain the optical properties of the incorporated fluorophore. The surface of the nanoparticles can be functionalized with a variety of active groups such as hydroxyl, thiol, amine, and carboxyl. The carboxyl groups on the surface were used to conjugate with various bioactive molecules such as transferrin, as well as monoclonal antibodies such as anti-claudin 4 and anti-mesothelin, for targeted delivery to pancreatic cancer cell lines. In vitro experiments have revealed that the cellular uptake of these bioconjugated (targeted) nanoparticles is significantly higher than that of the nonconjugated ones. The ease of surface functionalization and incorporation of a variety of biotargeting molecules, combined with their observed noncytotoxicity, makes these fluorescent ORMOSIL nanoparticles potential candidates as efficient probes for optical bioimaging, both in vitro and in vivo.


Subject(s)
Microscopy, Fluorescence/methods , Nanostructures/chemistry , Nanotechnology/methods , Rhodamines/chemistry , Silicon Dioxide/chemistry , Contrast Media/chemistry , Cross-Linking Reagents/chemistry , Crystallization/methods , Drug Carriers/chemistry , Drug Delivery Systems/methods , Fluorescent Dyes/chemistry , Macromolecular Substances/chemistry , Materials Testing , Molecular Conformation , Nanostructures/ultrastructure , Particle Size , Surface Properties
2.
J Phys Chem B ; 111(25): 6969-72, 2007 Jun 28.
Article in English | MEDLINE | ID: mdl-17552555

ABSTRACT

In this study, CdSe/CdS/ZnS quantum dots (QDs) were used as optical contrast agent for imaging pancreatic cancer cells in vitro using transferrin and anti-Claudin-4 as targeting ligands. CdSe/CdS/ZnS was chosen because the CdSe/CdS/ZnS QDs have better photoluminescence (PL) efficiency and stability than those of CdSe/ZnS. The transferrin-mediated targeting is demonstrated in both a cell-free coprecipitation assay as well as using in vitro confocal microscopy. Pancreatic cancer specific uptake is also demonstrated using the monoclonal antibody anti-Claudin-4. This targeted QD platform will be further modified for the purpose of developing as an early detection imaging tool for pancreatic cancer.


Subject(s)
Contrast Media , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/pathology , Quantum Dots , Cell Line, Tumor , Humans , Microscopy, Electron, Transmission
3.
Nano Lett ; 7(3): 761-5, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17288490

ABSTRACT

Live cell imaging using CdSe/CdS/ZnS quantum rods (QRs) as targeted optical probes is reported. The QRs, synthesized in organic media using a binary surfactant mixture, were dispersed in aqueous media using mercaptoundecanoic acid (MUA) and lysine. Transferrin (Tf) was linked to the QRs to produce QR-Tf bioconjugates that were used for targeted in vitro delivery to a human cancer cell line. Confocal and two-photon imaging were used to confirm receptor-mediated uptake of QR-Tf conjugates into the HeLa cells, which overexpress the transferrin receptor (TfR). Uptake was not observed with QRs that lacked Tf functionalization or with cells that were presaturated with free Tf and then treated with Tf-functionalized QRs.


Subject(s)
Nanotubes/chemistry , Quantum Dots , Fluorescent Dyes , HeLa Cells , Humans , Microscopy, Confocal , Microscopy, Electron , Microscopy, Fluorescence, Multiphoton , Molecular Probes/chemistry , Nanotechnology , Nanotubes/ultrastructure , Transferrin/pharmacokinetics
4.
J Nutr ; 134(6): 1406-11, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15173404

ABSTRACT

A wealth of evidence indicates that consumption of fish or dietary fish oils containing long-chain (n-3) PUFA such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is associated with cardiovascular benefit, including a reduction in circulating triacylglycerol concentrations and reduced mortality from coronary heart disease. Shorter-chain dietary (n-3) PUFA such as alpha-linolenic acid from vegetable oils are inefficiently converted to EPA and DHA and do not possess the hypotriglyceridemic properties attributed to fish oils. The objective of this study was to investigate the effect of dietary Echium oil, a plant oil containing the 18-carbon (n-3) PUFA stearidonic acid, on tissue fatty acid content and serum triacylglycerol concentrations in hypertriglyceridemic humans. Asymptomatic subjects with mild-to-moderate hypertriglyceridemia were enrolled in an open-labeled study. Subjects underwent a 4-wk lead-in period and were then instructed to follow the National Cholesterol Education Program Step 1 diet. Subjects (n = 11) whose serum triacylglycerol concentrations remained between 3.4 and 5.1 mmol/L (300 and 450 mg/dL) were instructed to consume 15 g of Echium oil daily for 4 wk. During the treatment period, serum triacylglycerol concentrations decreased by 21%, or 0.87 +/- 0.26 mmol/L (mean +/- SD) compared with baseline (P < 0.05); 8 of 11 subjects had a decrease in serum triacylglycerols ranging from 13 to 52% with a decrease from baseline of 30%, or 1.26 +/- 0.41 mmol/L (mean +/- SD). There were no significant changes in any other clinical laboratory variables. Concentrations of long-chain (n-3) PUFA, including EPA, increased (P < 0.05) in plasma and neutrophils when subjects consumed Echium oil. In conclusion, dietary plant oils rich in stearidonic acid are metabolized to longer-chain, more unsaturated (n-3) PUFA. These oils appear to possess hypotriglyceridemic properties typically associated with fish oils.


Subject(s)
Dietary Fats, Unsaturated/pharmacology , Echium , Fatty Acids, Omega-3/blood , Hypertriglyceridemia/blood , Neutrophils/metabolism , Plant Oils/pharmacology , Triglycerides/blood , Aged , Cell Line, Tumor , Cells, Cultured , Fatty Acids, Omega-3/metabolism , Female , Humans , Male , Middle Aged
5.
Clin Ther ; 25(3): 948-71, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12852710

ABSTRACT

BACKGROUND: Numerous studies have explored dietary-management strategies for decreasing leukotriene synthesis by inflammatory cells through supplementation with polyunsaturated fatty acids such as gamma-linolenic acid (GLA) and eicosapentaenoic acid (EPA). OBJECTIVES: This study sought to determine the optimal daily intake, ratios, and formulation of dietary GLA and EPA required to safely reduce leukotriene biosynthesis in healthy individuals, and to evaluate the pharmacokinetics and safety profile of such a formulation. METHODS: Two preliminary trials were conducted to determine the minimum effective levels of GLA and EPA intake needed to reduce leukotriene biosynthesis and prevent increases in plasma arachidonic acid (AA) concentrations. These preliminary trials were followed by a single-center, randomized, double-blind, placebo-controlled, parallel-group, escalating-intake inpatient trial of a dietary GLA/EPA emulsion (PLT 3514) in healthy adult subjects. Subjects consumed either 10, 20, or 100 g of the PLT 3514 emulsion (respectively containing 0.75 g GLA + 0.5 g EPA, 1.5 g GLA + 1 g EPA, and 7.5 g GLA + 5 g EPA), or a placebo emulsion containing olive oil daily for 14 days. Plasma fatty acids were measured by gas chromatography Stimulated whole blood leukotrienes were measured by high-performance liquid chromatography with ultraviolet detection. RESULTS: Thirty subjects were included in the preliminary trials; 47 subjects were enrolled in the escalating-intake trial, of whom 42 completed the study. In the preliminary trials, intake of GLA 1.5 g/d in gelatin capsules decreased the capacity to synthesize leukotrienes but increased plasma levels of AA (both, P < 0.05). Inclusion of 0.25 or 1 g of dietary EPA prevented the increase in plasma AA concentrations. Dietary GLA and EPA showed significantly enhanced bioavailability when consumed in 20 g PLT 3514 emulsion compared with consumption in gelatin capsules (P < 0.05), resulting in a reduction in the amount of intake required to block leukotriene biosynthesis. Pharmacokinetic analyses indicated that fasting plasma GLA and EPA levels plateaued within 7 days' daily consumption at all levels of intake, whereas the time to maximum plasma concentration (Tmax) was shorter for GLA than for EPA. The Tmax was similar on days 1 and 14 for both GLA and EPA. There were no clinically significant between-group differences in changes in vital signs, mean clinical laboratory values, or abbreviated hematology laboratory tests, or significant differences in the occurrence of treatment-emergent adverse events between the group consuming up to 20 g/d of the GLA/EPA emulsion and the group consuming placebo. CONCLUSION: Consumption of specific proportions and intake levels of dietary GLA and EPA in a novel emulsion formulation inhibited leukotriene biosynthesis and appeared to be well tolerated in this population of healthy adult subjects.


Subject(s)
Fatty Acids, Unsaturated/pharmacology , Fatty Acids, Unsaturated/pharmacokinetics , Food, Formulated , Leukotriene B4/biosynthesis , Adult , Analysis of Variance , Arachidonic Acid/blood , Arachidonic Acid/metabolism , Double-Blind Method , Eicosapentaenoic Acid/pharmacokinetics , Eicosapentaenoic Acid/pharmacology , Emulsions , Fatty Acids/blood , Female , Headache/etiology , Humans , Leukotriene B4/antagonists & inhibitors , Leukotriene B4/blood , Male , Nausea/etiology , Treatment Outcome , gamma-Linolenic Acid/pharmacokinetics , gamma-Linolenic Acid/pharmacology
6.
Clin Ther ; 25(3): 972-9, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12852711

ABSTRACT

BACKGROUND: Leukotriene inhibitors and leukotriene-receptor antagonists are effective in the treatment of inflammatory diseases such as asthma. A search of the entirety of MEDLINE using the terms diet plus leukotrienes identified numerous studies that have explored dietary-management strategies to reduce leukotriene levels through supplementation with polyunsaturated fatty acids such as gamma-linolenic acid (GLA) and eicosapentaenoic acid (EPA). However, the search found no studies on the use of combinations of these fatty acids in patients with asthma. OBJECTIVE: The goal of this study was to determine the effect of daily intake of an emulsion (PLT 3514) containing dietary GLA and EPA on ex vivo stimulated whole blood leukotriene biosynthesis in patients with atopic asthma. METHODS: This was a randomized, double-blind, placebo-controlled, parallel-group, prospective trial in patients with mild to moderate atopic asthma. Patients consumed 10 g PLT 3514 emulsion (containing 0.75 g GLA + 0.5 g EPA), 15 g PLT 3514 emulsion (containing 1.13 g GLA + 0.75 g EPA), or placebo (olive oil) emulsion daily for 4 weeks. Plasma fatty acids were measured by gas chromatography, and stimulated whole blood leukotrienes were measured by reverse-phase high-performance liquid chromatography with ultraviolet detection using a diode array detector. RESULTS: Forty-three patients (33 women, 10 men) participated in the study. Leukotriene biosynthesis was significantly decreased in patients consuming 10 or 15 g PLT 3514 compared with placebo (P < 0.05, analysis of covariance). No clinically significant changes in vital signs were observed throughout the study, and there were no significant between-group differences in treatment-emergent adverse events or mean clinical laboratory values. CONCLUSION: Daily consumption of dietary GLA and EPA in a novel emulsion formulation inhibited leukotriene biosynthesis in this population of patients with atopic asthma and was well tolerated.


Subject(s)
Asthma/therapy , Fatty Acids, Unsaturated/therapeutic use , Food, Formulated , Leukotriene A4/biosynthesis , Adult , Asthma/blood , Double-Blind Method , Eicosapentaenoic Acid/therapeutic use , Emulsions , Fatty Acids/blood , Female , Humans , Leukotriene A4/antagonists & inhibitors , Leukotriene A4/blood , Male , Prospective Studies , gamma-Linolenic Acid/therapeutic use
7.
J Rheumatol ; 30(2): 355-63, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12563696

ABSTRACT

OBJECTIVE: To investigate the usefulness of a novel retinoic acid receptor (RAR) antagonist (BMS-189453) in animal models of arthritis. METHODS: BMS-189453 was tested in HIG-82 rabbit synovial fibroblasts to determine its ability to repress collagenase (matrix metalloproteinase-1, MMP-1) mRNA expression in vitro. Cells were stimulated with phorbol myristate acetate or interleukin 1 beta and mRNA quantified by slot-blot analysis. In vivo, BMS-189453 was evaluated in 2 animal models of arthritis: collagen induced arthritis (CIA) in mice and streptococcal cell wall induced arthritis (SCWA) in rats. Clinical scores for arthritis were recorded weekly. At the end of each study, limbs were evaluated histologically. In CIA, these results were correlated with mRNA levels for collagenase-3 (MMP-13) and stromelysin-1 (MMP-3) as determined by Northern blot. RESULTS: BMS-189453 reduced MMP-1 expression in HIG-82 synovial fibroblasts in culture. BMS-189453 treatment blocked the clinical progression of arthritis beyond soft tissue inflammation in the CIA model. In the SCWA model, BMS-189453 treatment resulted in significantly reduced swelling with no notable progression to joint distortion/destruction. Histological evaluation of the joints from animals in both models confirmed this result. Analysis of mRNA from the CIA paws showed that BMS-189453 prevented the overexpression of MMP-13 and MMP-3 in arthritic joints. CONCLUSION: Improvement in clinical and histologic variables in 2 separate animal models, along with simultaneous reduction in MMP expression in the affected joint, suggests that RAR antagonists such as BMS-189453 may be useful as agents to treat rheumatoid arthritis and for determining the role of MMP in disease progression. This is the first study to show the clinical potential of RAR antagonists in arthritis.


Subject(s)
Arthritis, Experimental/drug therapy , Retinoids/antagonists & inhibitors , Retinoids/pharmacology , Animals , Arthritis, Experimental/pathology , Carcinogens/pharmacology , Collagenases/genetics , Disease Models, Animal , Female , Fibroblasts/cytology , Fibroblasts/drug effects , Gene Expression Regulation, Enzymologic/drug effects , In Vitro Techniques , Interleukin-1/pharmacology , Matrix Metalloproteinase 1/genetics , Matrix Metalloproteinase 13 , Matrix Metalloproteinase 3/genetics , Mice , Mice, Inbred DBA , Rabbits , Rats , Rats, Inbred Lew , Receptors, Retinoic Acid/antagonists & inhibitors , Retinoids/chemistry , Synovial Membrane/cytology , Tetradecanoylphorbol Acetate/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...